Myeloma Clinical Trials in Boston, Massachusetts
49 recruitingBoston, Massachusetts
Showing 1–20 of 49 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Not Applicable
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled31 locationsNCT07266441
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell MyelomaPlasma Cell Myeloma
ECOG-ACRIN Cancer Research Group1,450 enrolled600 locationsNCT04566328
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 2
Elranatamab in R/R Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Massachusetts General Hospital32 enrolled3 locationsNCT06138275
Recruiting
Phase 2
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Plasma Cell Myeloma Refractory
Sanofi64 enrolled34 locationsNCT06356571
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Multiple Myeloma
Boston Medical Center10,000 enrolled1 locationNCT00898235
Recruiting
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Multiple MyelomaAcute Kidney InjuryLight Chain Nephropathy
Brigham and Women's Hospital450 enrolled1 locationNCT06483139
Recruiting
Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Multiple MyelomaRelapseMultiple Myeloma in Relapse+1 more
Andrew Yee, MD43 enrolled3 locationsNCT04176718
Recruiting
Not Applicable
HEME Home Transfusion Program
LymphomaLeukemiaHematologic Malignancy+3 more
Dana-Farber Cancer Institute700 enrolled2 locationsNCT06487247
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb260 enrolled17 locationsNCT05372354
Recruiting
Not Applicable
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Bone PainMetastatic Malignant Neoplasm in the BonePlasma Cell Myeloma
University of Southern California100 enrolled9 locationsNCT03858205